DEVELOPMENT OF FIRST-IN-CLASS OCULAR THERAPEUTICS

To develop best-in-class ocular therapeutics to address urgent unmet clinical needs posed by ocular surface disease.

Our team of experienced researchers are passionate about advancing medical science and improving patient outcomes through innovative research:

Dr. Brad Young is a biotechnology executive and consultant with over 20 years of experience developing and commercializing target medicine products and services, in the disease areas of ophthalmology, oncology, and immune and vascular diseases.

Dr. Sandeep Jain is a clinician-scientist and B.A. Field Professor of Ophthalmology at the UIC Department of Ophthalmology. He is the Director of the UIC Dry Eye and ocular Graft-Vs-Host Disease clinic. His research work is funded by NIH and has led to more than 75 peer-reviewed publications, multiple patents, start-ups and development of drugs. 

Dr. Simon Kaja is an Endowed Professor of Ophthalmology at Loyola University Chicago where he maintains an NIH-funded program in drug discovery for ocular surface disease. Simon serves as Scientific Advisor to eyeNOS. 

Dr. Kun Don (Sue) Yi is an expert in toxicology and safety pharmacology. Trained as a neuropharmacologist, Sue contributes her scientific and regulatory expertise to eyeNOS. 

Dr. Keith Jones is Professor of Molecular Pharmacology and Neuroscience at Loyola University Chicago and co-founder of eyeNOS. Keith is an internationally recognized expert in pharmacology and drug delivery. 

Dr. Dimitrios Karamichos is Professor of Pharmaceutical Sciences and Pharmacology & Neuroscience at the University of North Texas Health Science Center at Fort Worth and serves as the Executive Director of the North Texas Eye Research Institute. Dimitri is an international expert in corneal disease.